CTLA4 and gastric cancer: In the GC mouse model with the treatment of anti–CTLA-4 mAbs, the autophagy-related risk score was significantly decreased at week 3 compared with the untreated group from the study by Nagaoka et al. (Figure 4L) (Nagaoka et al., 2020).